Could an Immune-Boosting drug ease long COVID? small trial launches
NCT ID NCT07108036
First seen Oct 31, 2025 · Last updated Jun 22, 2026 · Updated 27 times
Summary
This Phase 2 trial is testing the safety of a drug called Anktiva (N-803) in 20 adults with Long COVID. Participants receive up to two doses and are monitored for side effects and changes in symptoms. The goal is to see if this immune-boosting drug is safe enough to study further for treating Long COVID.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California - San Francisco
RECRUITINGSan Francisco, California, 94110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anktiva (nogapendekin alfa inbakicept, also called N-803)
What this could lead to
If this trial shows Anktiva is safe and well-tolerated in Long COVID, it could point toward a new treatment option to ease lingering symptoms.
What could go wrong
This is a very small, early-phase study (20 people) focused only on safety, not on whether the drug actually helps symptoms. It may not lead to any proven benefit.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.